leisure time -WSS

leisure time

author：Wikipedia 2025-09-27 22:49:21 - browse：6258

Portrait of Don Davis -- health policy coverage from STAT — U.S. Representative Don Davis (D-N.C.) Wikimedia Commons

WASHINGTON — Two Republican lawmakers who introduced legislation to water down the Inflation Reduction Act’s Medicare drug price negotiation program managed to find themselves a Democratic co-sponsor — even though every single Democrat in Congress in 2022 voted for the legislation.

They found their perfect candidate in Rep. Don Davis, a Democrat representing a North Carolina district that includes parts of the state’s Research Triangle. He came to Washington in 2023, so didn’t vote on the original law. He received donations in 2023 from the political action committees for Gilead, Astellas, Genentech, Bayer, Pfizer, Novo Nordisk, GSK, Bristol Myers Squibb, BIO, Amgen, Boehringer Ingelheim, Merck, AbbVie, and Eli Lilly.

“We must support the development of critical, life-sustaining medical treatments and cures,” Davis said in a written statement, and a spokesperson declined to elaborate. He is joined on the bill by Rep. Greg Murphy (R-N.C.) and Brett Guthrie (R-Ky.), the Energy and Commerce health subcommittee chairman.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Living organ donors deserve priority status for transplants

hotspot

WSS

How to fix the rural physician shortage in the U.S.

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Bispecific antibodies are next new thing in cancer immunotherapy

Why the advice to take all your antibiotics may be wrong

Eli Lilly’s Mounjaro succeeds in second weight

It's time to take a new tack for treating Alzheimer's

entertainment

leisure time

explore

Drug repurposing or repositioning? The language matters

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

After affirmative action ruling, medical educators look to 'holistic review'

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Wildfire smoke exposes gaps in outdoor worker protections

Pfizer's RSV vaccine recommended for approval in Europe

FDA approval of Sarepta Duchenne genetic therapy gives me hope

How Brent Saunders' Allergan experiment failed

Activists slam private health insurers over coverage restrictions

Novo: Oral version of Ozempic leads to 15% weight loss

hotspot

What is artificial intelligence? Experts weigh in

Study: Misdiagnosis causes 800,000 deaths, serious disabilities a year in U.S.

Why the advice to take all your antibiotics may be wrong

Novo: Oral version of Ozempic leads to 15% weight loss

Pfizer's RSV vaccine recommended for approval in Europe

New chart reveals military’s vast involvement in Operation Warp Speed

leisure time

hotspot

knowledge

hotspot